AbbVie Inc. (ABBV34.SA)
São Paulo - São Paulo Delayed price. Currency in BRL
Add to watchlist
At close: 01:01PM BRT
| Previous close | 51.39 |
| Open | 51.50 |
| Bid | 50.39 x 0 |
| Ask | 53.00 x 0 |
| Day's range | 50.45 - 53.00 |
| 52-week range | 39.68 - 57.77 |
| Volume | |
| Avg. volume | 5,844 |
| Market cap | 1.427T |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | 46.71 |
| EPS (TTM) | 1.08 |
| Earnings date | 25 July 2024 - 29 July 2024 |
| Forward dividend & yield | 1.46 (2.89%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
PR NewswireAbbVie Completes Acquisition of Landos Biopharma
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP). With the completion of the acquisition, Landos is now part of AbbVie.
ZacksWhy AbbVie (ABBV) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ZacksLilly (LLY) Hits Record High on Crohn's Disease Study Data
Eli Lilly's (LLY) stock hits an all-time high after announcing detailed results from a late-stage study on mirikizumab in Crohn's disease.
© 2024 Yahoo. All rights reserved.